Refine by
Oncology Articles & Analysis: This-Year
26 articles found
Lipids are not merely structural components of cellular membranes—they also act as powerful signaling molecules that orchestrate key physiological processes. Among the enzymes regulating lipid signaling, ENPP2 (Ectonucleotide Pyrophosphatase/Phosphodiesterase 2), also known as autotaxin, plays a central role by converting lysophosphatidylcholine (LPC) into the bioactive lipid ...
Chemokines and their receptors form one of the most intricate signaling networks in immunology. Among them, CCR1 (C-C chemokine receptor type 1) has attracted attention for its dual role as both a guardian of host defense and a potential driver of chronic inflammation and cancer progression. For researchers, CCR1 is more than a seven-transmembrane G protein–coupled receptor (GPCR)—it ...
Many oncology drugs have been abandoned by pharmaceutical companies due to poor performance in phase I, II, or III clinical trials. These drugs represent untapped potential treatments for indications outside of those initially investigated. With research and development costs for a single new drug estimated between $2–3 billion, abandoned drugs represent an opportunity to bring drugs to ...
Population growth, aging populations and increases in cancer incidence have necessitated new approaches to identifying effective treatments. One such approach involves the repositioning, or repurposing, of drugs already FDA approved in either non-oncology disease states and/or approved in a limited number of tumor types. The repurposing of these drugs for new indications represents an ...
Human ovarian epithelial cells play a crucial role in ovarian function and have become a significant focus in cancer research, specifically ovarian cancer. The ability to study these cells in a laboratory setting has been greatly enhanced through the development of immortalized human ovarian epithelial cell lines, particularly those that utilize the SV40 (Simian Virus 40) large T antigen. ...
Adenoviruses are a group of viruses that have gained significant attention in recent years, particularly in the fields of gene therapy, vaccine development, and cancer treatment. With their ability to deliver genetic material into cells effectively, adenoviruses serve as valuable vectors in various biomedical applications. To harness their potential, specialized adenovirus production services ...
Introduction PEGylation, the process of attaching polyethylene glycol (PEG) chains to therapeutic molecules, has become a cornerstone in pharmaceutical development. This technique improves the pharmacokinetic and pharmacodynamic properties of drugs, enhancing their stability, solubility, and circulation time while reducing immunogenicity. Since its first FDA-approved application in 1990 with ...
The BCL2 gene, short for B-cell lymphoma 2, is a critical regulator of apoptosis, or programmed cell death. It belongs to a larger BCL2 gene family, which includes both pro-apoptotic and anti-apoptotic proteins that maintain a delicate balance between cell survival and cell death. Dysregulation of this gene family is implicated in a variety of diseases, most notably cancer. What is BCL2? The ...
Active Pharmaceutical Ingredients (APIs) form the foundation of modern pharmaceuticals, serving as the biologically active components responsible for the therapeutic effects of medications. These crucial compounds undergo rigorous research, development, and manufacturing processes before being integrated into final pharmaceutical formulations. The pharmaceutical landscape encompasses a diverse ...
In this white paper, Predictive Oncology (POAI) highlights a recent successful project in partnership with the University of Michigan Natural Products Discovery Core (NPDC) through the ACE program. The ACE program supports academic researchers in their early drug discovery and development initiatives by providing access to the POAI proprietary active machine learning platform and ...
Alfa Cytology has revealed new FAP-targeted therapeutics development services that aim to develop precise and effective cancer treatments. Alfa Cytology has introduced its groundbreaking initiative which targets fibroblast activation protein(FAP) for cancer therapies. These solutions focusing on FAP to improve treatment accuracy and deliver customized projects that strive to obtain more ...
Circulating Tumor Cells, or CTCs, are cancer cells that have shed from the primary tumor and enter the bloodstream, where they can travel and potentially lead to metastasis. These cells are of significant interest in oncology due to their potential to provide vital information about the tumor’s characteristics and behavior. One of the advanced techniques used to analyze CTCs is Fluorescence ...
In recent years, the field of antibody drug design has become increasingly significant in the realm of therapeutic development, driven by the need for more effective and targeted treatments for various diseases, including cancer, autoimmune disorders, and infectious diseases. Antibodies, which are proteins produced by the immune system, have the ability to specifically recognize and bind to ...
Histological image analysis has emerged as a pivotal domain in biomedical research and clinical diagnostics, allowing scientists and healthcare professionals to decipher the intricate structures of tissues at a microscopic level. This analysis encompasses the examination of biological tissues to understand their composition, organization, and pathology, which can be crucial for diagnosing ...
Alfa Cytology has officially released its antibody-drug conjugates(ADCs) development services which demonstrates the dedication to fighting cancer through advanced treatment methods. Alfa Cytology, which stands at the forefront of oncology service provision in New York United States, has announced its sophisticated antibody-drug conjugates(ADCs) development services for cancer. The pioneering ...
Antibody-Drug Conjugates (ADCs) represent a groundbreaking advancement in targeted cancer therapy, combining the specificity of antibodies with the potency of cytotoxic drugs. The development and production of ADCs are complex processes that require a deep understanding of both biology and chemistry, alongside cutting-edge technology. This article delves into the intricacies of ADC development ...
The advent of organoid technology has transformed biomedical research through the development of 3D models that precisely replicate human organ structures and functions in a physiological context. Creative Bioarray establishes itself as a world leader in life science innovation through its complete range of organoid services that enhance drug discovery, disease modeling, and personalized ...
In the realm of drug discovery, the search for innovative therapies often leads to new paradigms. One such paradigm that has gained significant traction in recent years is the development of PROTAC (Proteolysis Targeting Chimeras) technology. This groundbreaking approach unlocks new potential in targeting previously “undruggable” proteins, paving the way for transformative therapies ...
In the ever-evolving landscape of cancer research, two intriguing concepts have emerged that are reshaping how scientists approach treatment: synthetic lethality and parthanatos. Both concepts encapsulate the complexity of cellular processes and open new avenues for targeted therapies. What is Synthetic Lethality? Synthetic lethality occurs when the simultaneous disruption of two genes ...
Alfa Cytology unveils advanced PD-1 inhibitor development service for cancer research. Alfa Cytology, a prominent service provider in the oncology landscape, has recently launched its innovative PD-1 inhibitor development services. This initiative marks a significant advancement in the quest for more effective cancer therapies, focusing on enhancing precision and adaptability in treatment ...